ERC Advanced Grant · 2024
Direct on Sputum Sequencing to Interrupt Transmission of Rifampicin Resistant Tuberculosis
The DiSrupT RR-TB pragmatic cluster randomized trial (CRT) will tackle the ongoing public health threat of rifampicin-resistant tuberculosis (RR-TB) and prevent the emergence of bedaquiline-resistant tuberculosis (BDQR-TB) as a new public health crisis. The trial aims to evaluate an innovative all-in-1 solution for whole genome sequencing (WGS): the recently launched QIAseq xHYB Mtb assay for WGS directly on sputum (dWGS) in combination with Illumina sequencing and the novel digital MAGMA-MICK platform for automated analysis, interpretation, and communication of dWGS results to health care workers. The intervention aims to provide optimal treatment for all patients (precision medicine) and…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.